A unique heterocyclic carbamate prodrug of seco-CBI-indole(2) that releases no residual byproduct is reported as a new member of a class of hydrolyzable prodrugs of the duocarmycin and CC-1065 family of natural products. The prodrug was designed to be activated by hydrolysis of a carbamate releasing the free drug without the cleavage release of a traceable extraneous group. Unlike prior carbamate prodrugs examined that are rapidly cleaved in vivo, the cyclic carbamate was found to be exceptionally stable to hydrolysis under both chemical and biological conditions providing a slow, sustained release of the exceptionally potent free drug. An in vivo evaluation of the prodrug found that its efficacy exceeded that of the parent drug, that its therapeutic window of efficacy versus toxicity is much larger than the parent drug, and that its slow free drug release permitted the safe and efficacious use of doses 150-fold higher than the parent compound.
A unique heterocyclic carbamate prodrug of n class="Chemical">seco-CBI-indole(2) that releases no residual byproduct is reported as a new member of a class of hydrolyzable prodrugs of the duocarmycin and CC-1065 family of natural products. The prodrug was designed to be activated by hydrolysis of a carbamate releasing the free drug without the cleavage release of a traceable extraneous group. Unlike prior carbamate prodrugs examined that are rapidly cleaved in vivo, the cyclic carbamate was found to be exceptionally stable to hydrolysis under both chemical and biological conditions providing a slow, sustained release of the exceptionally potent free drug. An in vivo evaluation of the prodrug found that its efficacy exceeded that of the parent drug, that its therapeutic window of efficacy versus toxicity is much larger than the parent drug, and that its slow free drug release permitted the safe and efficacious use of doses 150-fold higher than the parent compound.
Authors: M Ichimura; T Ogawa; K Takahashi; E Kobayashi; I Kawamoto; T Yasuzawa; I Takahashi; H Nakano Journal: J Antibiot (Tokyo) Date: 1990-08 Impact factor: 2.649
Authors: L H Hurley; C S Lee; J P McGovren; M A Warpehoski; M A Mitchell; R C Kelly; P A Aristoff Journal: Biochemistry Date: 1988-05-17 Impact factor: 3.162
Authors: D G Martin; C Biles; S A Gerpheide; L J Hanka; W C Krueger; J P McGovren; S A Mizsak; G L Neil; J C Stewart; J Visser Journal: J Antibiot (Tokyo) Date: 1981-09 Impact factor: 2.649
Authors: E Kobayashi; A Okamoto; M Asada; M Okabe; S Nagamura; A Asai; H Saito; K Gomi; T Hirata Journal: Cancer Res Date: 1994-05-01 Impact factor: 12.701
Authors: Ryan C Conyers; Jennifer R Mazzone; Maxime A Siegler; Abhai K Tripathi; David J Sullivan; Bryan T Mott; Gary H Posner Journal: Bioorg Med Chem Lett Date: 2014-01-30 Impact factor: 2.823
Authors: Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Douglas Brown; George A Vielhauer; Dale L Boger Journal: J Med Chem Date: 2013-05-10 Impact factor: 7.446
Authors: Jennifer R Mazzone; Ryan C Conyers; Abhai K Tripathi; David J Sullivan; Gary H Posner Journal: Bioorg Med Chem Lett Date: 2014-04-16 Impact factor: 2.823
Authors: Christopher J Collins; Leslie A McCauliff; Seok-Hee Hyun; Zhaorui Zhang; Lake N Paul; Aditya Kulkarni; Klaus Zick; Mary Wirth; Judith Storch; David H Thompson Journal: Biochemistry Date: 2013-04-30 Impact factor: 3.162
Authors: Amanda L Wolfe; Katharine K Duncan; James P Lajiness; Kaicheng Zhu; Adam S Duerfeldt; Dale L Boger Journal: J Med Chem Date: 2013-08-29 Impact factor: 7.446